Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety, Immunogenicity and Efficacy of Low Dose Nivolumab in Adults Living With HIV on Antiretroviral Therapy (ART)

NCT05187429 is registered in ClinicalTrials.gov with University of Melbourne as lead sponsor.

NCT NCT05187429
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05187429 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety, Immunogenicity and Efficacy of Low Dose Nivolumab in Adults Living With HIV on Antiretroviral Therapy (ART)
Lead sponsor
University of Melbourne
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 24, 2023
Completion date
January 31, 2029
Enrollment
42 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hiv i infection